vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of vTv Therapeutics in a report on Thursday, June 2nd.

vTv Therapeutics Stock Up 4.7 %

NASDAQ:VTVT opened at $0.90 on Monday. The company has a fifty day moving average of $0.70 and a 200-day moving average of $0.69. The firm has a market capitalization of $81.03 million, a P/E ratio of -3.75 and a beta of -1.55. vTv Therapeutics has a twelve month low of $0.38 and a twelve month high of $2.17.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $2.00 million for the quarter. On average, analysts anticipate that vTv Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cim Investment Management Inc. grew its holdings in shares of vTv Therapeutics by 100.0% during the 4th quarter. Cim Investment Management Inc. now owns 354,746 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 177,373 shares during the period. Rafferty Asset Management LLC lifted its position in vTv Therapeutics by 26.7% in the 4th quarter. Rafferty Asset Management LLC now owns 69,067 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 14,537 shares in the last quarter. Finally, Samsara BioCapital LLC bought a new position in vTv Therapeutics in the 4th quarter valued at approximately $1,627,000. Institutional investors own 7.35% of the company’s stock.

vTv Therapeutics Company Profile

(Get Rating)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

Featured Articles

• Get a free copy of the StockNews.com research report on vTv Therapeutics (VTVT)
• Use These To Find Your Stock’s Support and Resistance Levels
• Is Boeing Stock is Ready for Lift-Off ?
• Elon Musk is Out, But Should You Be In Twitter Stock?
• 3 Earnings Announcements That Could Surprise
• Twitter’s Up For Third Week In A Row: What’s Next For The Stock?

Want More Great Investing Ideas?